tradingkey.logo

Tenax Therapeutics Inc <TENX.OQ> expected to post a loss of 19 cents a share - Earnings Preview

ReutersMay 9, 2025 2:34 PM
  • Tenax Therapeutics Inc TENX.OQ TENX.O is expected to show no change in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Tenax Therapeutics Inc is for a loss of 19 cents per share.

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Tenax Therapeutics Inc is $20.00​, above​ its last closing price of $5.82. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.15

-0.42

-0.18

Beat

57.4

Sep. 30 2024

-1.40

-1.39

-0.19

Beat

86.3

Jun. 30 2024

-1.99

-1.98

-1.83

Beat

7.8​

Mar. 31 2024

-2.48

-2.40

-3.12

Missed

-30

​​Dec. 31 2023

-8.11

-8.14

-12.98

Missed

-59.4

Sep. 30 2023

-4.80

-7.20

-6.40

Beat

11.1​

Jun. 30 2023

-7.90

-8.00

-4.00

Beat

50

Mar. 31 2023

-29.60

-29.60

-12.00

Beat

59.5

This summary was machine generated May 9 at 14:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI